Please assess the completion status of the following clinical trial:

Trial Title: Losartan and Inflammation in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CF patients homozygous for F508del and on current treatment with Orkambi™ for at least 3 months~* Age \>12 years~* Forced expiratory volume at one second (FEV1) \>/= 40% of predicted~Exclusion Criteria:~* Female patients not willing to adhere to strict birth control (combination of two methods)~* Pregnancy~* History of intolerance to angiotensin receptor blockers (ARBs)~* Treatment with angiotensin converting enzyme (ACE) inhibitor~* NPD response to zero chloride (0Cl)/isoproterenol of \> - 6.6 mV at screening (evidence of detectable CFTR activity at baseline)~* Regular use of NSAIDs or potassium supplementation, treatment with aliskiren, on anticoagulation~* Oral corticosteroid use within 6 weeks~* Exacerbation requiring treatment within 6 weeks~* Active treatment for mycobacterial infections~* Significant hypoxemia (oxygen saturation \<90% on room air and rest or use of continuous oxygen treatment), chronic respiratory failure by history (pCO2 \> 45 mmHg), clinical evidence of cor pulmonale~* Untreated arterial hypertension (systolic blood pressure \>140 mm Hg, diastolic blood pressure \> 90 mmHg)~* Blood pressure less than 90 mm Hg systolic while standing~* Cardiac, renal (creatinine 1.5 times normal limit), hepatic (LFTs \> 3x normal upper limit), neurological, psychiatric, endocrine or neoplastic diseases that are judged to interfere with participation in study~* Known renal artery stenosis~* Concomitant airway disorders other than CF, such as allergic bronchopulmonary aspergillosis (ABPA).~* Subjects with prior thoracic surgery

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Losartan group (Type: EXPERIMENTAL): Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).
- Placebo group (Type: PLACEBO_COMPARATOR): Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.

Based on this trial design, predict the completion outcome and termination type (if applicable).